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Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, FinlandCerebral ischemia activates endogenous reparative processes,
such as increased proliferation of neural stem cells (NSCs) in
the subventricular zone (SVZ) andmigration of neural progen-
itor cells (NPCs) toward the ischemic area. However, this repar-
ative process is limited because most of the NPCs die shortly af-
ter injury or are unable to arrive at the infarct boundary. In this
study, we demonstrate for the ﬁrst time that endogenous
mesencephalic astrocyte-derived neurotrophic factor (MANF)
protects NSCs against oxygen-glucose-deprivation-induced
injury and has a crucial role in regulating NPC migration. In
NSC cultures, MANF protein administration did not affect
growth of cells but triggered neuronal and glial differentiation,
followed by activation of STAT3. In SVZ explants, MANF over-
expression facilitated cell migration and activated the STAT3
and ERK1/2 pathway. Using a rat model of cortical stroke, in-
tracerebroventricular injections of MANF did not affect cell
proliferation in the SVZ, but promoted migration of double-
cortin (DCX)+ cells toward the corpus callosum and infarct
boundary on day 14 post-stroke. Long-term infusion of
MANF into the peri-infarct zone increased the recruitment of
DCX+ cells in the infarct area. In conclusion, our data demon-
strate a neuroregenerative activity of MANF that facilitates dif-
ferentiation and migration of NPCs, thereby increasing
recruitment of neuroblasts in stroke cortex.Received 2 July 2017; accepted 18 September 2017;
https://doi.org/10.1016/j.ymthe.2017.09.019.
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Neurogenesis persists in the adult rodent brain within the subventric-
ular zone (SVZ) and the subgranular layer of the hippocampus.1–3
Neural stem cells (NSCs) of the SVZ give rise to neural progenitor
cells (NPCs) that migrate through the rostral migratory stream to
the olfactory bulb, where they differentiate into granule and periglo-
merular neurons throughout the adult life of rodents.4,5 Ischemic
injury drastically increases neurogenesis in the rodent SVZ,6 and
the surviving neuroblasts migrate out of the SVZ into the striatum
and mature into functional neurons.7 Moreover, transient angiogen-
esis after stroke allows neuroblasts to migrate along newly formed
blood vessels, aiding in their migration out of the SVZ.8 In the model
of cortical stroke, themajority of NPCs either fail to reach the lesioned238 Molecular Therapy Vol. 26 No 1 January 2018 ª 2017 The Author(
This is an open access article under the CC BY-NC-ND license (httpcortex or differentiate into glial cells due to a non-permissive environ-
ment for neuronal differentiation.9,10 Therefore, attempts to utilize
the therapeutic potential of these cells to replace lost neurons in the
infarct cortex have had limited success.11,12
Small secreted proteins, such as growth factors, regulate survival, dif-
ferentiation, and maturation of neurons during development.13 In the
adult brain, they support the survival of neurons and regeneration of
axons after injury,14 making them good candidates to be used for
enhancing recovery after stroke. For example, glial cell line-derived
neurotrophic factor (GDNF) and GDNF family receptor alpha 1
(GFRa1) promote differentiation and tangential migration of cortical
GABAergic neurons during brain development.15 Additionally,
GDNF has a chemoattractant effect in the migration of neuronal pre-
cursor cells along the rostral migratory stream (RMS),16 and studies
on GFRa1 knockouts demonstrate its role in the development and
function of the olfactory system.17
In the stroke model, GDNF was found to promote the proliferation of
NPCs in the SVZ and their recruitment into the damaged striatum.18
Similarly, administration of brain-derived neurotrophic factor
(BDNF) stimulates post-stroke neurogenesis.19 Additionally, our pre-
vious data demonstrate that adeno-associated virus (AAV)-BDNF
transduction enhances the migration of SVZ cells toward the lesioned
hemisphere in stroke rats.20
Unlike GDNF or BDNF, mesencephalic astrocyte-derived neurotro-
phic factor (MANF), together with its homolog cerebral dopamine
neurotrophic factor (CDNF), are non-classical neurotrophic factors
that reside in the endoplasmic reticulum (ER) and are secreted
from cells in response to ER stress.21–25 MANF has been shown to
be upregulated by the unfolded protein response (UPR) ands).
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. MANF Expression in the P35 Mouse Brain
(A) Coronal cortical sections from P35 brains stained with MANF antibody from WT
and Manf/ mice. The insets show photomicrographs of the cortex at higher
magnification and immunostained with MANF antibody. (B and C) Double immu-
nofluorescent labeling was performed to determine the localization of MANF (red).
Neurons and astrocytes were identified by NeuN (B) and GFAP (C) (green),
respectively. (D) Photomicrographs of coronal sections of the SVZ and striatum
stained with MANF antibody from WT and Manf/ mice. The insets show the SVZ
at higher magnification immunoreactive for MANF antibody. (E) SEZ and SVZ
double-labeled for Nestin (green) and MANF (red) antibodies. (F) Section of
SVZ from adult mouse double-labeled with DCX (green) and MANF (red) antibodies.
(G) Coronal sections of the SEZ and SVZ stained with GFAP (green) and MANF (red)
antibodies; (H) for BrdU (green) and MANF (red) antibodies. Scale bars, 20 mm (A
and D inset) and 50 mm (C and E–H). CTX, cerebral cortex; SEZ, subependymal
zone.
www.moleculartherapy.orgstroke,21,22,26 and lack of MANF leads to chronic UPR in the pancre-
atic islets in vivo.27 We previously demonstrated that MANF has a
neuroprotective effect in the distal middle cerebral artery occlusion
(dMCAo) model of cerebral ischemic injury.28,29 Recently, MANF
has been shown to promote tissue repair and improve the success
of photoreceptor replacement therapies in the damaged retina.30
In this study, we ﬁrst aimed to characterize the effects of MANF on
NSCs in the homeostatic condition and with a stress insult. We deter-
mined the role of MANF in NPCmigration and its possible molecular
mechanisms by administration of exogenous MANF or by modifying
Manf expression levels in in vitro SVZ explants. Furthermore, we
used an in vivo cortical stroke model to test the effect of MANF in
neuroblast migration from the SVZ.
RESULTS
MANF Is Expressed in Both Mitotic NSCs and NPCs and Post-
mitotic Neurons in the Adult Brain
The speciﬁcity of MANF antibodies was validated by comparing wild-
type (WT) and Manf/ cortical sections. We found MANF expres-
sion in the cerebral cortex of WT but notManf/ mice (Figure 1A).
MANF was co-localized with NeuN, but not with glial-associated in-
termediate ﬁlament (GFAP), in the cortex of a mature mouse brain
(Figures 1B and 1C), suggesting that MANF protein was mainly ex-
pressed in mature neurons. Notably, MANF was also strongly ex-
pressed in the adult SVZ of WT mice (Figure 1D) and co-localized
with Nestin, doublecortin (DCX), and GFAP (Figures 1E–1G).
Importantly, BrdU+ cells in the SVZ also expressed MANF (Fig-
ure 1H). These results show that MANF is not only expressed in
mature cortical neurons, but also in SVZ cells, including quiescent
NSCs (type B cells, GFAP+), transient amplifying progenitors (type
C cells, Nestin+), and neuroblasts (type A cells, DCX+) of the adult
brain.
Administration of MANF Does Not Affect Growth or Self-
Renewal of NSCs but Triggers Neuronal and Glial Differentiation
A strong immunoﬂuorescent signal for MANF was found in the
culturedWTNSCs, and no signal was observed inManf/ cells (Fig-
ure 2A). First, we analyzed the diameter of neurospheres and found
no difference in the size of neurospheres between WT and Manf/Molecular Therapy Vol. 26 No 1 January 2018 239
Figure 2. MANF Stimulates STAT3 Signaling Pathways in NSC/NPC Cultures
(A) Immunofluorescent staining against MANF (green) shows high signal in WT and no signal in Manf/ neurospheres. (B) Representative images of the neurospheres in
24-well plates on DIV5. Treatment with rhMANF (400 ng/mL) induced morphological changes in WT and Manf/ neurospheres, including asymmetrical conformation
and induction of neurite-like processes. (C) Administration of rhMANF (400 ng/mL) did not increase the diameter of neurospheres derived from WT and Manf/ mice.
(D) Administration of exogenous MANF to WT or MANF-deficient cells does not affect the proportion of self-renewing NSCs (n = 8). The ability of single cells to form new
neurospheres was evaluated after 7 days of culture in EGF/FGF-containing stem cell medium. (E) Representative photomicrographs of NSC/NPCs in neurospheres
labeled for Nestin (green), TuJ1 (green), or GFAP (red), and nuclei were counterstained with DAPI (blue). (F) Lysates from WT and MANF/ NPCs, treated with vehicle or
rhMANF for 4 days, subjected to immunoblot analysis to determine levels of tubulin (TuJ1) and GFAP. (G) Protein levels were quantified as relative levels compared to
GAPDH, n = 3, Student’s t test, **p < 0.01. (H) Neurospheres, grown in the NSC medium, were incubated with rhMANF (400 ng/mL) for 0, 1, 6, and 24 hr. Thereafter,
lysates were prepared and western blot was performed using the indicated antibodies. (I and J) The presence of rhMANF did not increase the phosphorylation of AKT or
ERK1/2 in neurospheres. P-AKT (I) and p-ERK (J) were normalized to AKT and ERK, respectively. The levels are shown as fold change to control cells. (K) rhMANF
induced sustained p-STAT3-Tyr705 increase that lasted until 24 hr. P-STAT3-Tyr were normalized to Pan-STAT3 and presented as fold change to control (n = 5, one-way
ANOVA, p = 0.004; ***p < 0.001; **p < 0.01). (L) rhMANF increased phosphorylation of STAT3-Ser727 that lasted until 6 hr. P-STAT3-Ser was normalized to Pan-
STAT3 and presented as fold change to control cells (n = 5, one-way ANOVA, p = 0.03; *p < 0.05). Scale bars, 50 mm (A) and 100 mm (B and E). Data are presented as
mean ± SEM.
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www.moleculartherapy.orggroups (Figures 2B and 2C), indicating that loss of MANF did not
affect growth of neurospheres. Next, we studied the effect of endoge-
nous MANF on self-renewal of NSCs and found there was a similar
self-renewal rate of NSCs between the genotypes. Single cell suspen-
sion of WT or Manf/ NSCs were treated either with recombinant
human MANF (rhMANF) (400 ng/mL) or vehicle (PBS), and we
did not observe any effects of exogenous rhMANF on the percentage
of NSCs forming new neurospheres (Figure 2D). However, many
rhMANF-treated WT and Manf/ NSCs showed localized budding
and cellular process extensions, implying that the cells had under-
gone morphological changes (Figure 2B). Immunoﬂuorescence re-
vealed stronger expression of TuJ1, a marker for neuron-speciﬁc
tubulin, and GFAP, an intermediate ﬁlament marker for glial cells,
in rhMANF-treated neurospheres (Figure 2E). Moreover, western
blot analysis revealed increased levels of TuJ1 and GFAP in
rhMANF-treated neurospheres compared to non-treated, but Nestin
levels were similar between the groups (Figures 2F and 2G). Previ-
ously, MANF and CDNF have been reported to act like classical
neurotrophic factors (NTFs) by extracellularly promoting cell sur-
vival via activation of the PI3K-AKT pathway.31,32 To test whether
the trophic effects of MANF on NSCs are mediated through AKT or
other pathways, neurospheres were treated with 400 ng/mL
rhMANF for 0, 1, 6, and 24 hr (Figure 2H). However, the time-
course analysis revealed that rhMANF did not trigger AKT or
ERK1/2 activation (Figures 2I and 2J). Interestingly, addition of
rhMANF to NSCs revealed a 4-fold increase in phosphorylation
of STAT3 tyrosine705 (Figure 2K). The increase was observed at
1 hr and the levels remained high until 24 hr after MANF admin-
istration. Also, rhMANF stimulated the phosphorylation of
STAT3 on Ser727 and there was a signiﬁcant increase at 1 and
6 hr after MANF addition, but there was no statistically signiﬁcant
increase at the 24-hr time point (Figure 2L). Together, these results
demonstrate that endogenous and exogenous MANF do not affect
the growth or self-renewal of NSCs, but exogenous MANF triggered
neuronal and glial differentiation, which was accompanied by
increased STAT3 phosphorylation.
Loss of MANF Increases NSC Vulnerability to OGD- and
Reoxygenation-Induced Stress
Previously, MANF has been shown to rescue neurons from
apoptosis.28,33,34 Therefore, we investigated whether MANF had a
protective effect on NSC under 40 min of oxygen-glucose deprivation
(OGD), followed by 24 hr re-oxygenation (Figure 3A). We quantiﬁed
the proportion of activated caspase-3+ cells and found signiﬁcantly
increased numbers of activated caspase-3+ cells in Manf/ NSCs
compared to WT (Figures 3B and 3C). Moreover, the apoptotic
rate in Manf/ NSCs exposed to OGD and reoxygenation was
decreased with rhMANF treatment (Figures 3B and 3C). Next, we
used propidium iodide (PI) staining to re-assess the viability of WT
and Manf/ NSCs. In normoxic conditions, the percentage of
apoptotic cells was similar betweenWT andManf/cells (Figure 2K,
24.9% ± 2.9 [n = 6] versus 25.2% ± 1.3 [n = 6], respectively). However,
after 40 min OGD and 24 hr reoxygenation, the proportion of dying
Manf/ cells was signiﬁcantly higher compared to dying WT cells(Figure 3D). Moreover, pre-treatment of rhMANF signiﬁcantly
decreased the percentage of PI+Manf/ cells (Figure 3D), indicating
that administration of rhMANF could partially rescue Manf/ cells
from dying. Taken together, the above data suggest that deletion of
MANF increases vulnerability of NSCs to OGD-induced stress and
administration of rhMANF could, at least partially, compensate for
the lack of MANF in Manf/ NSCs.
MANF Regulates Cell Migration in SVZ Explants
Next, we examined whether endogenous MANF is involved in the
neuronal migration, a critical step in brain development. We iso-
lated the SVZ fragments from WT and Manf/ embryos (E19)
and cultivated these in Matrigel to investigate the migration of cells
from SVZ explants. At days in vitro 2 (DIV2), few cells had
migrated from the explant (Figures 4A and 4B). At DIV7, many
cells were found in the periphery of the WT explant. However, cells
lacking MANF showed a shorter distance of migration (Figures 4A
and 4B) compared to WT cells. These data suggest that endogenous
MANF is essential for migration of cells from SVZ explants
in vitro.
Because endogenous MANF is essential for embryonic SVZ cell
migration in vitro, we investigated whether administration of
rhMANF further promotes cell migration from the postnatal SVZ ex-
plants. SVZ explants collected from mouse brains were treated daily
with rhMANF (0, 200, 400, and 800 ng/mL) or BDNF (25 ng/mL, pos-
itive control) on days 1–4. At DIV1, there was minimal migration of
cells (Figure 4C). At DIV4, treatment with 400 ng/mL MANF or
BDNF increased the cell migration distance (Figures 4C and 4D).
At DIV7, administration of MANF (200 and 400 ng/mL) increased
the distance of cell migration from SVZ explants when compared
to the vehicle group. However, rhMANF at a dose of 800 ng/mL
did not increase cell migration from SVZ explants (Figure 4D),
implying that exogenous MANF regulates cell migration in a dose-
dependent manner.
Overexpression of MANF Enhanced DCX+ Cell Migration from
SVZ Explants
Next, we investigated whether the lentivirus (LV)-mediated overex-
pression of hMANF in DCX+ cells induced their migration from
SVZ explants. As a control, we overexpressed a membrane-targeted
myristoylated serine-threonine protein kinase Akt1 that causes
constitutive activation of the Akt signaling pathway35 because the
Akt pathway has been shown to mediate migration of developing
neurons. In order to test the function of LV preparations, developing
cortical neurons were transduced with LV-hDCX-GFP, LV-hDCX-
myrAKT-GFP, and LV-hDCX-hMANF-IRES-GFP. 5 days after
transduction we observed GFP ﬂuorescence (green) in DCX+ cells
(red), which was indicative of successful transduction (Figures
5A–5C). Using a sensitive ELISA, we found that hMANF concentra-
tions were signiﬁcantly increased in cortical neuronal lysates
(Figure 5D) and in media (Figure 5E) after LV-hDCX-hMANF-
IRES-GFP treatment when compared to neurons transduced by
LV-hDCX-GFP or LV-hDCX-myrAKT-GFP.Molecular Therapy Vol. 26 No 1 January 2018 241
Figure 3. MANF Is Protective against OGD in NSCs
(A) Timeline of the oxygen-glucose-deprivation/re-
perfusion experiment. (B) Representative photomicro-
graphs of activated caspase-3 labeling in the NSCs after
OGD or under normal conditions. (C) Ratio of activated
caspase-3+ cells in relation to DAPI+ nuclei. Increase in
activated caspase-3 density in Manf/ cells after OGD
treatment compared to WT cells. rhMANF treatment
before OGD decreased activated caspase-3 density in
Manf/ cells (n = 6–11, two-way ANOVA, genotype X
condition effect p = 0.042; **p < 0.01 genotype effect;
*p < 0.05 Manf/ OGD versus OGD + rhMANF). (D)
Analysis of cell death by PI labeling. The percentage of PI+
Manf/ nuclei after OGD and reoxygenation was higher
than in WT cells, indicating a greater apoptotic rate in
Manf/ cells. OGD-induced Manf/ cell death was
prevented by rhMANF treatment (n = 6 to 7, two-way
ANOVA, genotype X condition effect p = 0.001; ***p <
0.001 genotype comparison; *p < 0.05 Manf/ OGD
versus OGD + rhMANF). Scale bar, 100 mm (B). Data are
presented as mean ± SEM.
Molecular TherapyCultured SVZ explants were transduced with LV-hDCX-GFP (Fig-
ure 5F), LV-hDCX-myrAKT-GFP (Figure 5G), or LV-hDCX-
hMANF-IRES-GFP (Figure 5H) on DIV1. Compared to control
treatments, MANF overexpression enhanced the distance of cell
migration at DIV6 (Figures 5F–5J). Moreover, MANF-overexpress-
ing neuroblasts migrate in a chain-like form distal to the explants
(Figure 5H, panel 2). Although high expression of myrAkt1 in
DCX+ cells increased the number of neuroblasts with pronounced
neurite-like processes surrounding the SVZ explants, it did not
noticeably increase the distance of cell migration from SVZ explants
(Figures 5G, 5I, and 5J). These data suggest that stimulation of the242 Molecular Therapy Vol. 26 No 1 January 2018Akt pathway may increase the number of neu-
roblasts but does not promote their migration.
Contrarily, overexpression of MANF enhances
the migration of neuroblasts from SVZ ex-
plants, probably by regulating signaling mech-
anisms other than the Akt-mTOR pathway in
DCX+ cells.
Overexpression of MANF Activates STAT3
and ERK1/2 during SVZ Cell Migration
Although a signal-transducing receptor for
MANF has not been identiﬁed, MANF can
exert its neurotrophic or neuroprotective ef-
fects through intracellular signals. Thus, we
hypothesized that overexpression of MANF
regulates molecular mechanisms involved
in the migration of SVZ cells. We found
increased levels of phosphorylated Akt
(p-Akt) in SVZ explants after LV-hDCX-myr-
AKT-GFP transduction at DIV4 and DIV7
(Figures 6A–6C). Moreover, myrAKT signiﬁ-cantly increased the levels of phosphorylated ribosomal protein
S6 (p-S6K) at DIV4 and DIV7 (Figures 6D–6F), but did not stim-
ulate ERK activation (Figures 6G–6I), indicating that myrAKT spe-
ciﬁcally activated the AKT/mTOR pathway. Conversely, overex-
pression of MANF did not increase p-AKT and p-S6K levels but
signiﬁcantly activated the p-ERK/ERK pathway on DIV4 (Figures
6G and 6I). However, there was no difference in the ratio of
p-ERK1/2 to ERK1/2 between groups on DIV7 (Figures 6H
and 6I), suggesting overexpressed MANF only increased phosphor-
ylation of ERK1/2 at the beginning of cell migration. In line, over-
expression of MANF also increased the level of p-STAT3-SER727
Figure 4. Effects of MANF on Cell Migration from the
SVZ Explants
(A) Representative images of SVZ explants at DIV2 and
DIV7 from WT and Manf/ embryos. (B) MANF-deficient
cells from the SVZ explants migrate shorter distances than
WT cells at DIV7 (two-way ANOVA, genotype X time effect
p = 0.02; **p < 0.01 TK, n = 7 to 8). (C) 64 SVZ explants
treated with rhMANF (0, 200, 400, and 800 ng/mL) or
rhBDNF (25 ng/mL) from day 1 to day 4 and representative
photomicrographs are shown from DIV1 and DIV7.
(D) BDNF and MANF treatments significantly increased
the migration of cells (n = 7 to 8, two-way ANOVA,
treatment  time p < 0.01). At DIV4, the migration of cells
was significantly increased from BDNF and rhMANF
(400 ng/mL) treated SVZ explant (**p < 0.05, TK). At DIV7,
BDNF and rhMANF (200 and 400 ng/mL) treatments
enhanced the distance of migration (***p < 0.001 TK).
Scale bars, 500 mm (A) and 1,000 mm (C). TK, Tukey’s
post hoc test. Data are presented as mean ± SEM.
www.moleculartherapy.orgat DIV4, and it returned to baseline levels at DIV7 (Figures 6J–6L).
Although MANF has been implicated in regulating UPR markers,
there was no difference in GRP78 protein levels between groups
at any time points (Figures 6M–6O). Together, these results suggest
that overexpressed MANF promotes migration of DCX+ cells as
well as regulates STAT3 and ERK1/2 activation.
DCX+ Cells in SVZ, Neocortex, and Corpus Callosum after
dMCAo
To clarify the pattern of neuroblast migration in the cortical stroke
model, adult rats were sacriﬁced 2, 7, 14, and 28 (n = 4) days after
dMCAo and the number of DCX+ cells were quantiﬁed in the SVZ,
corpus callosum, and infarction area (Figure S1A). We did not
observe any DCX+ cells in the neocortex in non-stroked rats. How-
ever, the dMCAo-lesioned rats exhibited increased numbers of
DCX+ cells in the ipsilateral SVZ from day 2 post-stroke (Figure S1B).
On day 14 post-stroke, we found few DCX+ cells in the infarcted
neocortex composed of infarcted core and ischemic penumbra (Fig-
ure S1A). The DCX+ cells in the infarcted area of neocortex had aMolemorphology resembling that of differentiated
post-migratory neurons with branched pro-
cesses (Figure S1A, day 14, arrow). More
DCX+ cells were observed in the ipsilateral
corpus callosum, and these cells exhibited a
migratory morphology, with leading and trail-
ing processes (Figure S1A, day 14, arrowhead).
Quantiﬁcation of DCX+ cell numbers in the
ipsilateral and contralateral SVZ, infarcted
area of the neocortex, and corpus callosum
beneath the infarction core revealed a signiﬁcant
increase in the number of DCX+ cells in the ipsi-
lateral SVZ on days 2, 7, 14, and 28 compared to
the non-stroke group (Figure S1B). Moreover,
the number of DCX+ cells in the corpus cal-losum was highest on post-stroke day 14, implying that the number
of neuroblasts observed in the corpus callosum beneath the infarction
zone is time dependent.
MANF Did Not Affect NPC Proliferation in the SVZ but Promoted
the Migration of DCX+ Cells toward the Infarct Boundary
Stroke rats were stereotaxically injected with GDNF (n = 5), rhMANF
(n = 6), or vehicle (n = 6) into their right (ipsilateral to stroke) lateral
ventricles on days 3, 7, and 10 after dMCAo. BrdU was administered
from days 3 to 10, and brains were collected on day 14 (Figure 7A).
There was no difference in infarction size among the three groups
(Figures 7B and 7C). As expected, GDNF treatment enhanced
BrdU incorporation in the SVZ ipsilateral to the lesion (Figures 7D
and 7E). The increased number of BrdU-labeled cells in the SVZ of
GDNF-treated animals suggests increased cell proliferation. Immu-
noreactivity for DCX was examined in 17 stroke rats on day 14
post-stroke. GDNF treatment signiﬁcantly increased the density of
DCX immunoreactivity in the ipsilateral SVZ (Figures 7F and 7G).
However, MANF treatment neither increased cell proliferation norcular Therapy Vol. 26 No 1 January 2018 243
Figure 5. Transduction of SVZ cells with LV-MANF Enhances Cell Migration
from SVZ Explants Derived from P1 Mouse Brain
(A–C) Embryonic cortical neurons transduced with LV-hDCX-GFP (A), LV-hDCX-
myrAKT-GFP (B), and LV-hDCX-hMANF-IRES-GFP (C) after 5 days in culture.
Photomicrographs show immunofluorescent labeling of neurons with anti-DCX
(red), and anti-GFP (green) and counterstained with DAPI (blue). (D and E) MANF
protein concentration in cell lysates (D, n = 5 to 6) and culture media (E, n = 3 to 4)
from embryonic cortical neurons transduced with indicated LVs (one-way ANOVA
p < 0.001, ***p < 0.001 compared to GFP, TK). (F–H) Representative photomi-
crographs of SVZ explants on the left. Panels 1 and 2 show immunostaining for DCX
(red) and counterstaining with DAPI (blue) in the migrating cells from SVZ explants.
The proximal (F1) and distal (F2) area of migrating DCX+ cells transduced with LV-
GFP (F). (G) Representative images of myrAKT-expressed SVZ explants. (G1) The
density of DCX-stained cells close to SVZ explants was increased when compared
to GFP controls. (G2) High density of migrating DCX+ cells distal to SVZ explants. (H)
Representative photomicrographs of LV-MANF-treated SVZ explants. (H1) Immu-
nofluorescent staining of DCX+ cells close to SVZ explants. (H2) Overexpression of
MANF in SVZ resulted in chains of neuroblasts, whichmigrated further from explants
at DIV6 compared to controls. (I) Quantified migration distance at DIV1 in all groups
(n = 4 to 5) and at DIV6 revealed increased cell migration from SVZ explants
transduced with LV-MANF as compared to the GFP group (n = 11 to 12, one-way
ANOVA, p = 0.02; *p < 0.05 TK). (J) Quantification of migratory distance of cells from
SVZ explants. MANF increased the migratory distance of cells migrating from SVZ
explants (n = 18–22, one-way ANOVA p = 0.0005, **p < 0.01 compared to GFP and
myrAKT, TK). Scale bars, 50 mm (A–C) and 100 mm (F–H). TK, Tukey’s post hoc test.
Data are presented as mean ± SEM.
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suggesting that MANF injections did not enhance the dMCAo-
induced proliferative response.36 Next, we quantiﬁed the number of
neuroblasts by counting DCX+ cells in different areas. GDNF mark-
edly increased the number of DCX+ cells in the ipsilateral striatum
and induced more chains of neuroblasts with long processes.
MANF also increased the number of DCX+ cells in the ipsilateral
striatum but did not inﬂuence their morphology (Figures 7H and
7I). Additionally, we examined the number of DCX+ cells in the
infarcted area of the neocortex and corpus callosum beneath the
infarction zone. Surprisingly, GDNF did not increase the number
of DCX+ cells within the infarct boundary on day 14 after dMCAo
(Figures 7J and 7K). Notably, compared to vehicle-treated and
GDNF-treated rats, MANF signiﬁcantly increased the number of
DCX+ cells in the corpus callosum and infarcted neocortex (Figures
7J–7M). Moreover, MANF induced recruitment of robust chains of
neuroblasts in the corpus callosum beneath the infarction zone
and promoted more neuroblasts with long, branched processes
in the infarcted neocortex. Taken together, these data reveal that
administration of MANF into the right lateral ventricle facilitates
migration of the NPCs to the injured cortex.
We next explored whether MANF, compared to GDNF, inﬂuences
the fate of newly generated cells 14 days after 90 min dMCAo.
MANF treatment markedly increased the number of cells labeled
with BrdU and DCX in the corpus callosum beneath the infarction
zone compared to vehicle and the GDNF-treated group (Figures 8A
and 8B). There was a trend toward fewer cells double labeled with
BrdU and the astrocyte marker GFAP in the infarcted area of the
neocortex in the MANF and GDNF treatment groups (Figures 8C
Figure 6. Overexpression ofMANFActivates ERK1/2
and STAT3 Signaling in the SVZ Explant Culture
SVZ explants were transduced with LV on DIV1 and
analyzed using western blotting at DIV4 or DIV7. (A and B)
The expression of myrAKT at DIV4 (A) and DIV7 (B) were
detected in LV-myrAKT-transduced SVZ explants. (C)
Quantitated level of myrAKT relative to GAPDH (n = 3, two-
way ANOVA, time  LV treatment, p < 0.01, ***p < 0.001
compared toGFP, TK). (D and E) Increased expressions of
phospho-S6K (P-S6K) was detected at DIV4 (D) and DIV7
(E) in LV-myrAKT-treated SVZ explants. (F) Quantification
of P-S6K level relative to GAPDH and increased levels
were observed in LV-myrAKT-treated explants (two-way
ANOVA, treatment effect p < 0.001, **p < 0.01, ***p <
0.001 compared to GFP TK). (G and H) Increased
expression of p-ERK1/2 in MANF-overexpressed SVZ
explants at DIV4 (G), but not at DIV7 (H). (I) Quantified
expression levels of p-ERK compared to total ERK
showed statistically significant elevated levels of p-ERK in
LV-MANF at DIV4 compared to LV-GFP and LV-myrAKT
groups (two-way ANOVA, p < 0.05, ***p < 0.01, TK) but
not at DIV7. (J and K) Overexpression of MANF induced
p-STAT3-Ser in SVZ explants at DIV4 (J), but not at DIV7
(K). (L) Statistically significant elevated levels of p-STAT3-
Ser in LV-MANF at DIV4 compared to LV-GFP and LV-
myrAKT groups (two-way ANOVA, p < 0.05, ***p < 0.001,
TK), but not at DIV7. (M–O) There was a modest expres-
sion of the UPR-regulated protein GRP78 at DIV4 (M) and
DIV7 (N), and it did not differ between groups at either time
point (O). TK, Tukey’s post hoc test. Data are presented as
mean ± SEM.
www.moleculartherapy.organd 8D).Meanwhile, the number of BrdU+ cells co-expressing the oli-
goprogenitor cell marker NG2 was not different among the three
groups (Figures 8E and 8F). Thus, the administration of MANF after
cortical stroke may have selectively affected the migrating immature
cells of the neuronal lineage.
Long-term Infusion of MANF Increased Recruitment of DCX+
Cells in Infarct Cortex
We tested whether long-term infusion of MANF increases the
number of newborn neurons in the lesioned cortex. Using osmotic
minipumps, GDNF, MANF, or vehicle were infused into the peri-
infarction zone for post-dMCAo days 3–16 and the rats were
euthanized 1 week later (Figure 9A). Lesion size did not differ
among the three groups (Figures 9B and 9C). GDNF infusion re-
sulted in a trend of increasing numbers of DCX+ cells in the right
SVZ and corpus callosum on day 24 after stroke (FiguresMole9D–9G), suggesting that GDNF infusion into
the peri-infarction zone might enhance
stroke-induced neurogenesis in the ipsilateral
SVZ. In contrast to GDNF, MANF infusion
did not increase the number of DCX+ cells in
the SVZ nor in the corpus callosum. Impor-
tantly, we observed that GDNF and MANF
treatments increased the number of DCX+cells in the infarct area of the neocortex (Figures 9H and 9I). These
results suggest that GDNF, a classical chemoattractant, increases
the number of NPCs close to where it is administered. However,
MANF seems to directly enhance migration of neuroblasts toward
the lesioned cortex.
We continued to explore whether MANF or GDNF promotes
neuronal maturation of the NPCs in the lesioned cortex by using
double-label immunoﬂuorescence. Stroke rats treated with long-
term infusion with GDNF (n = 5), MANF (n = 5), or vehicle
(n = 5) were injected with BrdU and sacriﬁced on day 24 after
dMCAo. Epiﬂuorescent microscopic examination indicated that
few BrdU+ cells in the lesioned cerebral cortex expressed the post-
mitotic neuronal markers NeuN and MAP2. Due to the diffuse
staining pattern of MAP2, it was difﬁcult to determine the co-local-
ization of BrdU and MAP2 (data not shown). There was a marginalcular Therapy Vol. 26 No 1 January 2018 245
Figure 7. Post-stroke Treatment with GDNF
Enhances Neurogenesis in the SVZ, but MANF
Promotes Migration of DCX+ Cells toward the
Infarction Area
(A) Timeline of treatment. (B) Representative photomi-
crographs of infarction areas in different groups. (C)
Infarction area was similar between groups. Nissl area
expressed as % of the whole area of the hemisphere. (D)
Representative photomicrographs of BrdU immunoreac-
tivity in the SVZ. (E) The number of BrdU-stained cells was
increased in ipsilateral SVZ of stroke rats receiving three
intraventricular injections of GDNF compared to vehicle or
MANF treated (dose of 10 mg, n = 5 to 6, one-way ANOVA
p < 0.01, *p < 0.05, ***p < 0.001 LSD. (F) Representative
photomicrographs of DCX immunoreactivity in the SVZ.
(G) GDNF injections increased DCX+ immunoreactivity in
the right SVZ compared to the MANF- or vehicle-treated
groups by almost 3-fold (one-way ANOVA p < 0.001,
***p < 0.001 TK). (H) Representative photomicrographs of
DCX immunoreactivity in the striatum. (I) GDNF or MANF
injections increased the recruitment of neuroblasts (DCX+
cells) into the striatum after stroke compared to vehicle by
4- and 2-fold, respectively (one-way ANOVAp < 0.05, *p <
0.05 TK). (J and L) Representative photomicrographs of
DCX immunoreactivity in the corpus callosum (J) and
infarction zone (L). (K and M) MANF promoted the
migration of DCX+ cells toward the right corpus callosum
by 3-fold (K; one-way ANOVA p < 0.001, **p < 0.01 TK)
and the infarct area of the neocortex by 3-fold (M; one-
way ANOVA p < 0.01, **p < 0.01 TK). No effect was
observed with GDNF. Scale bars, 2,000 mm (B) and 50 mm
(D–L). LSD, Fisher’s LSD post hoc test; TK, Tukey’s post
hoc test. Data are presented as mean ± SEM.
Molecular Therapyincrease in NeuN/BrdU density after MANF administration (Fig-
ures 9J and 9K).
DISCUSSION
We are the ﬁrst to demonstrate that MANF is robustly expressed in
adult SVZ cells. Loss of MANF does not affect self-renewal or
viability of NSCs in vitro. However,Manf/ NSCs are more vulner-
able to OGD- and reoxygenation-induced cell injury, and treatment246 Molecular Therapy Vol. 26 No 1 January 2018with MANF protein rescues apoptotic Manf/
cells. Although the extracellular application of
MANF had no mitogenic effect, it induced the
differentiation of NSCs, accompanied by
increased levels of neuron-speciﬁc tubulin and
glial-associated cytoskeleton protein as well as
activation of the STAT3 pathway. Additionally,
endogenous and exogenous MANF stimulated
cell migration from SVZ explants. Overexpres-
sion of endogenous MANF activated not only
STAT3 but also the ERK1/2 pathway at the
beginning of cell migration. In the cortical
ischemic-reperfusion injury experiments, intra-
cerebroventricular MANF injections promotedneuroblast migration toward the infarct boundary on day 14 post-
stroke. Furthermore, long-term infusion of MANF into the peri-
infarction zone increases the recruitment of neuroblasts within the
infarction area in the neocortex on day 24 post-stroke.
Our previous studies have shown that in neurons in vitro, MANF
is neuroprotective when it is expressed inside the cell.33,37 More-
over, a recent study showed that in order to be neuroprotective
Figure 8. MANF Injections, 3  10 mg, Resulted in
Increased Numbers of Neuroblasts in the Corpus
Callosum after Stroke
(A) Distribution of DCX+/BrdU+ cells in the corpus callosum
beneath the infarction zone. (B) Number of DCX+/BrdU+
cells in the ipsilateral corpus callosum increased due to
MANF treatment (n = 5 in all groups, one-way ANOVA p <
0.001, **p < 0.01, ***p < 0.001 TK). (C) GFAP immuno-
staining showed that most BrdU-labeled cells also express
GFAP in the infarction zone. (D) The number of GFAP+/
BrdU+ cells in the infarction zone did not differ between
groups. (E) NG2+ cells expressing BrdU within the infarct
boundary. (F) Number of BrdU+/NG2+ cells in the corpus
callosum beneath the infarction zone did not differ be-
tween treatment groups; scale bars, 50 mm. Data are
presented as mean ± SEM.
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Figure 9. Effect of Long-Term GDNF and MANF,
0.25 mg/mL, a total of 200 mL, Infusion in the Peri-
infarction Zone after Cortical Stroke
(A) A timeline of the experiment. (B) Representative pho-
tomicrographs of infarction areas in different groups. (C)
Staining and quantification of lesioned brain areas show
similar infarction sizes between groups, n = 5. (D–H) DCX+
cells after PBS, GDNF, or MANF administration in the SVZ
(D and E), corpus callosum (F and G), and infraction zone
(H). (I) GDNF and MANF treatments increase the number
of DCX+ cells in the infarction zone (n = 4 to 5, one-way
ANOVA p < 0.01, **p < 0.01 TK). (J) Images of NeuN
(green) and BrdU (red) double-labeled cells in the peri-
infarction zone. (K) A trend toward increase in the number
of new mature cortical neurons in the peri-infarction zone
with MANF treatment. n = 5. Scale bars, 2,000 mL (B),
50 mm (D–H), and 20 mm (J). Data are presented as
mean ± SEM.
Molecular Therapyin vitro MANF needs to be localized within the ER.37 Although
previous in vitro studies have shown that extracellular MANF
administration also has neuroprotective effects,38 the speciﬁc recep-
tor that MANF binds to on the plasma membrance was still
obscure.33 In this study, we examined the effects of MANF on
NSCs by deletion of Manf gene expression or administration of
exogenous MANF into the culture medium. We demonstrated
increased vulnerability of MANF-deﬁcient NSCs to OGD- and reox-
ygenation-induced stress and that administration of exogenous
rhMANF only rescued cells lacking MANF. However, exogenously
administered MANF protein did not show a protective effect for
WT cells, suggesting MANF plays a cell-autonomous role in NSC
survival from stress. Furthermore, these ﬁndings suggest that endog-
enous MANF plays a crucial role for NSC survival in OGD and re-248 Molecular Therapy Vol. 26 No 1 January 2018oxygenation stress. Additionally, we postulated
that endogenous MANF could be secreted
from WT NSCs after OGD and reoxygenation
injury and that the protective effect may be ex-
erted by MANF released from the injured cells,
masking the protective effect of exogenously
added MANF in the medium. A possible auto-
crine or paracrine mechanism could also
explain why MANF-deﬁcient NSCs are more
vulnerable to stress than WT cells and there-
fore responsive to rhMANF treatment.
MANF has been implicated as a neurotrophic
factor,39 and in the fruit ﬂy, is necessary for
the maturation of dopaminergic neurons.40
However, our data suggest a more extensive
regenerative role for MANF in the mammalian
brain. Because MANF is expressed in prolifer-
ating NSCs, we initially hypothesized that
MANF might be implicated in the regulation
of NSCs proliferation. However, the size andself-renewal of neurospheres were not affected by MANF removal
or exogenous administration in cultured NSCs. MANF did not affect
the number of BrdU+ cells after cortical ischemic injury, a state in
which NSC proliferation in the brain is induced. Thus, MANF seems
to be dispensable in the regulation of NSC proliferation. In particular,
because MANF did not affect proliferation of SVZ cells after stroke, it
could be an advantage for possible clinical use of MANF because
some growth factors could induce dysplastic and phenotypical
changes by stimulating uncontrolled cell proliferation.41,42
The signaling pathways activated by MANF are still largely unclear.
Recently, a study has shown that the administration at concentrations
higher than 1 mg/mL of rhMANF increased protein kinase C (PKC)
phosphorylation in a time-dependent manner.43 PKC has multiple
www.moleculartherapy.orgsubtypes and the subtypes have different effects; for example, PKCd
increases the activity of STAT3 and PKCɣ triggers ERK1/2 activa-
tion.44,45 We found that rhMANF treatment (400 ng/mL) activates
the STAT3 pathway during the process of neuronal and glial differen-
tiation of NSCs. STAT3 is a classic transcription regulator, which was
ﬁrst discovered as a key mediator of cytokine-induced inﬂammation
and immunity.46 Later studies have found STAT3 to regulate a wide
range of biological processes, including determining the fate of
NSCs.47,48 Many studies have reported that GFAP expression in
NPCs is dependent on the activation of STAT3 and its phosphoryla-
tion at Tyr705.49–51 Thus, STAT3 activation could be crucial for
astrocyte differentiation. Also, it has been suggested that STAT3 is
involved in neuronal differentiation and it regulates neuron-speciﬁc
microtubules by antagonizing the depolymerization activity of stath-
min.52 Importantly, serine-phosphorylated STAT3 localized to the
mitochondria instead of the nucleus is involved in neurite outgrowth
induced by nerve growth factor (NGF).53 In this study, we found that
STAT3 phosphorylation on Tyr705 and Ser727 is induced following
MANF treatment in primary NSCs. These ﬁndings led us to assume
that MANF could promote neuronal and glial differentiation via acti-
vation of STAT3 pathway. Although we did no further investigation
of whether inhibition of STAT3 signaling blocks the NSC differenti-
ation-promoting effect of exogenous MANF, the identiﬁcation of
NSCs as a target for MANF in our study may accelerate to clarify
the MANF-mediated signaling pathways. Meanwhile, exogenous
MANF did not activate ERK1/2 pathway in NSCs, which has been
suggested to be involved in Ser727 phosphorylation of STAT3,54
and the reason for this remains to be explored. Further studies will
be required to determine the putative MANF receptors on NSCs
and the mechanistic link between MANF and the STAT3 signaling
pathway.
Next, we showed that MANF has a role in NPC migration. LV-medi-
ated overexpression or extracellular administration of MANF en-
hances migration of cells from the SVZ explants, whereas lack of
MANF reduced it. In line with the effect of rhMANF on NSCs, over-
expressed MANF induced activation of STAT3 during SVZ cell
migration. Surprisingly, it also activated the ERK1/2 pathway at
DIV4. The ERK1/2 pathway regulates the differentiation of NSCs
through a number of mechanisms55–57 and is implicated in cell migra-
tion induced by growth factors.58 On the other hand, inhibition of
ERK activity has been shown to impair cell migration stimulated by
different growth factors, including vascular endothelial growth factor
(VEGF), epidermal growth factor (EGF), and ﬁbroblast growth factor
(FGF).59 Although the overexpression of MANF causes ERK1/2
phosphorylation in SVZ explants, we do not know whether this acti-
vation was directly induced by MANF or STAT3-related downstream
targets. Because phosphorylated and activated STAT3 upregulates
expression of genes encoding for growth factors such as VEGF or
HIF1a in many cell types,60 we assumed that the ability of MANF
to induce STAT3 activation can trigger neuronal and glial differenti-
ation preceding cell migration. However, it is also possible that
STAT3 activation by MANF increases the expression levels of growth
factors, which thereby activate cell membrane receptors and down-stream ERK1/2 signaling pathways, leading to increased cell
migration.
Cerebral ischemia can trigger endogenous repair processes and acti-
vate proliferation of NSCs. However, most of these cells die and do
not migrate to the lesioned area.7 GDNF has been shown to enhance
NSC proliferation in the SVZ and NPC recruitment to the ischemic
lesion.18 In this study, we observed that intraventricular injections
of GDNF increased cell proliferation in the SVZ, but not the number
of NPCs in the infarct boundary on day 14 post-stroke. There are
several possible explanations for this discrepancy. First, we utilized
a dMCAo model that restricts ischemic lesions mainly to the
neocortex without affecting the striatum. Meanwhile, Kobayashi
and coworkers18 used an intraluminal ﬁlament technique to generate
infarction in a broad brain area, including the striatum, and therefore,
increased NPC recruitment could have been caused by damage occur-
ring closer to the SVZ. Second, the GDNF infusion sites were
different. In our study, GDNF was infused into the lateral ventricle,
whereas Kobayashi and coworkers18 infused GDNF intra-striatally
so that GDNF diffused throughout the striatum, including the SVZ.
This could demonstrate that recruitment of neuroblasts to the
infarcted striatum may be due to the chemoattractant effect of
GDNF or secondarily due to the increased numbers of NPCs in the
SVZ. Previous studies have shown that compared to GDNF, MANF
diffuses in the brain signiﬁcantly better.34 Therefore, the increased
migration of NPCs from the SVZ toward the infarct area of the
neocortex could be attributable to a better distribution of MANF in
brain tissue. Particularly, we also found that in sham surgery rats
treated withMANF, there were no DCX+ cells moving to intact cortex
or only few DCX+ cells in the striatum, similar to the PBS group.
Contrarily, GDNF administration seemed to cause more DCX+ cells
in the striatum in the sham rats (data not shown), suggesting that
GDNF exerts chemoattractant effects to guide migration of the cells
in the SVZ. Moreover, MANF may have a direct effect on NPC
motility or improve the microenvironment in the lesioned area to
improve NPC migration.
Finally, we compared the effects of long-term local infusion of MANF
and GDNF into the peri-infarct region on the number of DCX+ cells
in the infarct area. In contrast to vehicle controls, local infusions of
MANF and GDNF increased the number of DCX+ cells in the infarct
cortex on day 24 post-stroke by 2-fold. However, neither MANF nor
GDNF signiﬁcantly increased the number of newly generated neu-
rons in the peri-infarct zone, implying that the migrating NPCs did
not further differentiate to mature neurons. In our study, the infusion
of MANF or GDNF continued for up to 16 days, similar to the tem-
poral pattern of ischemia-induced neurogenesis and neuroblast
migration described before.9 Although we have also found that
post-stroke MANF administration can induce behavioral improve-
ment (K. Mätlik, J.E.A., K.Y. Tseng, O.P. Smolander, E. Pakarinen,
L. Lehtonen, U. Abo-Ramadan, P. Lindholm, C. Zheng, B.K. Harvey,
U. Arumäe, M.L., and M.A., unpublished results), MANF treatment
did not accelerate neuronal maturation, which might occur at later
time points. Therefore, the MANF-induced behavioral recovery isMolecular Therapy Vol. 26 No 1 January 2018 249
Molecular Therapynot attributed to replacement of newly born neurons in the lesioned
cortex. We hypothesize that this beneﬁcial behavioral effect in stroke
rats may be due to the ability of MANF to improve a microenviron-
ment also supportive of migrating neuroblasts in lesioned sites; how-
ever, we cannot exclude involvement of other mechanisms to boost
functional recovery. A recent report showed that MANF, exerting im-
munomodulation, improves the success of cell-replacement regener-
ative therapies in the retina30 and the MANF paralog CDNF has an
anti-inﬂammatory function in nerve regeneration after spinal cord
injury.61 Because post-stroke inﬂammation has been implicated in
neuroblast migration2,62 and stroke-induced behavioral deﬁcit,63 it
is also possible that MANF could exert immune modulation to
both recruit neuroblasts toward the stroked cortex as well as to hasten
behavioral recovery.64–66
In conclusion, our results demonstrate that MANF treatment induces
differentiation of NSCs and increases cell migration from SVZ ex-
plants, preceded by activation of STAT3. Also, this is the ﬁrst study
to demonstrate the neuroregenerative potential ofMANF via promot-
ing neuroblast recruitment to the lesioned cortex in stroke rats.
MANF, distinct to GDNF, did not act as a classical growth factor,
which increases proliferation of SVZ cells. However, it promoted
migration of DCX+ cells into the damaged cortex. Taken together,
this study determines the effect of MANF in promoting the migration
of NPCs in vivo and in vitro and suggests MANF to improve the effec-
tiveness of stem-cell-based therapies for a damaged central nervous
system.MATERIALS AND METHODS
Isolation and Culturing of Manf–/– and WT NSCs
NSCs were prepared as previously described.67,68 Brieﬂy, the telen-
cephalons along with the lateral ventricle of E14.5 WT (Manf+/+)
and Manf/ mice were isolated and dissociated cells were cultured
in NSC growth medium containing DMEM/F12 (Gibco) supple-
mented with B27 (20 mL/mL, Gibco), EGF (20 ng/mL, Gibco),
FGF-2 (20 ng/mL, Gibco), GlutaMAX (10 mL/mL, Gibco), and peni-
cillin-streptomycin (50 U/mL, Gibco). After 5–7 days of culture, neu-
rospheres were dissociated by trituration and digestion (Accutase,
Gibco). Neurospheres were passaged every 7–10 days.OGD of Cultured Cells
We used previously described experimental procedures.69 Brieﬂy,
NSCs and NPCs were passaged and 2.5  105 cells were pre-incu-
bated for 4 hr in the growth medium. At ﬁrst, we examined the
viability of WT and mutant NSCs and NPCs in the normal condition
(20% O2; 5% CO2 and 74% N2) and this was considered as the con-
trol group. Then, the medium was replaced with a deoxygenated
glucose-free balanced salt solution (gfBSS) containing 120 mM
NaCl, 5 mM KCl, 1.25 mM NaH2PO4, 2 mM MgSO4, 25 mM
NaHCO3, 20 mM HEPES, and 2 mM CaCl2. WT and Manf
/ cells
were incubated in a hypoxic chamber (1%O2; remainder 5% CO2 and
94% N2) for 40 min and re-incubated in neurosphere medium for
24 hr. To examine the effects of exogenous MANF on cells, rhMANF250 Molecular Therapy Vol. 26 No 1 January 2018(200 ng/mL) was administered 15 min before 40 min OGD followed
by 24 hr reoxygenation.
Analysis of Cell Death with PI Staining and Flow Cytometry
To analyze cell death and apoptosis of NSCs and NPCs following
OGD, the cells were suspended into single cells by Accutase treat-
ment, ﬁxed with ice-cold 75% ethanol in PBS, and stained with
50 mg/mL PI (P5264, Sigma) for 5 min at 37C. The cells were
analyzed with a Gallios ﬂow cytometer (Beckman Coulter), and
data were analyzed using the Kaluza Flow Analysis 1.3 software
(Beckman Coulter). The apoptotic rate was calculated as the ratio
of PI+ cells to the total number of NSCs.70
Recombinant Proteins
rhMANF was produced in CHO cells (Icosagen, Tallinn, Estonia); re-
combinant human GDNF (rhGDNF) or recombinant human BDNF
(rhBDNF) was purchased from ProSpec-Tany TechnoGene (Reho-
vot, Israel) and R&D Systems (248-BD), respectively.
Construction of Transfer Plasmids and Production of Lentiviral
Vectors
A 2.2 kb fragment of human DCX promoter was PCR ampliﬁed using
Phusion high ﬁdelity DNA polymerase (Thermo Scientiﬁc) and the
following primers, BcuI_hDcx_for 50-ATACTAGTGGATACTT
GAGCTAAACTGCCT and EcoRI_hDcx_rev 50-TTGAATTCCCT
CAGAGACCTGA, digested with FastDigest-BcuI/-EcoRI (Thermo
Scientiﬁc), cloned into the pCDH-CMV-MSC-T2A-EGFP vector
(System Biosciences), and redigested with the same restriction en-
zymes. To obtain the pCDH-hDCX-IRES-GFP vector, the IRES-
GFP fragment was released from the pMX-IRES-GFP vector71 by
digestion with FastDigest-NotI/-SalI (Thermo Scientiﬁc), cloned
into the pCDH-hDCX-MSC-T2A-EGFP backbone, and redigested
with the same enzymes. Coding sequences of hMANF were PCR
ampliﬁed from human tissue cDNA with the following primers,
MANF_For 50 AATTTAAATCGGATCCACCATGTGGGCCACG
CAG, MANF_Rev TAGCGGCCGCGGATCCTACAAATCGGTCC
GTGCACTG, and cloned into a pCDH-hDCX-IRES-GFP vector di-
gested with FastDigest-BamHI (Thermo Scientiﬁc) using In-Fusion
cloning (Clontech) to obtain pCDH-hDCX-hMANF-IRES-GFP len-
tiviral transfer plasmids. Myristoylated constitutively active Akt1
(myrAkt) cDNA (Merck, #21-151) was cloned into the FastDigest-
EcoRI/-NotI-digested pCDH-hDCX-T2A-GFP vector. All plasmid
constructs were veriﬁed by DNA sequencing.
Lentiviral vectors (LVs) were produced as described,72–74 with the
following modiﬁcations. Brieﬂy, human HEK293T cells (ATCC
#CRL-1573) grown on 10-cm cell culture dishes in DMEM
(Gibco) with 10% fetal bovine serum (Gibco) and 1 mg/mL nor-
mocin (InvivoGen) were transfected using linear polyethylenimine
(Polysciences, #23966-2) with 10 mg transfer plasmid and 5 mg
each helper plasmids (pMDLg/pRRE, Addgene, #12251; pRSV/
REV, Addgene, #12253; and pMD2.G Addgene, #12259). At 5 to
6 hr post-transfection, the medium was changed to that contain-
ing 25 mM HEPES, pH 7.4. After 60 hr, supernatants were
www.moleculartherapy.orgcollected, ﬁltered, centrifuged, and re-suspended in Dulbecco’s
PBS (Gibco).
Primary Embryonic Cortical Neuron Cultures
Neocortical tissue from E16 embryos of timed, pregnant mice were
used to prepare neuronal cultures as described.75 Cells (7 104 viable
cells/well) were cultured in Neurobasal medium (Life Technologies)
supplemented with B27 (Life Technologies), 300 mM glutamine
(Life Technologies), and streptomycin and amphotericin B (Life
Technologies) and plated in 96-well plates coated with poly-D-lysine.
Cells were transduced with LV-hDCX-GFP, LV-hDCX-myrAkt-
GFP, or LV-hDCX-hMANF-IRES-GFP, respectively, on DIV1 using
MOI of 5. Cells were fed by 50% media exchange on DIV3. On DIV5,
the cells were ﬁxed with 4% paraformaldehyde (PFA) for 15 min and
immunostained.
ELISA for hMANF
hMANF protein levels were analyzed with an in-house-built sand-
wich ELISA speciﬁc for hMANF.76 Brieﬂy, a 96-well MaxiSorp plate
(Thermo Fisher) was coated with an anti-hMANF antibody. Samples
from developing cortical neurons were incubated overnight at +4C.
Horseradish-peroxidase-linked anti-hMANF antibody was used for
detection. Color was developed using the DuoSet ELISA Develop-
ment System (R&D). The hMANF concentration was normalized
to protein concentration determined by the Lowry method (DC Pro-
tein Assay, Bio-Rad).
SVZ Explant Cultures
Cultures were prepared from postnatal day (P) 3–5 mice. Brains were
dissected andz0.1 mm3 pieces of the SVZ were cultured on Matrigel
(Corning) coated 96-well plates (Neurobasal medium; 2% B27 sup-
plement; 2 mM GlutaMAX; and penicillin-streptomycin 50 U/mL,
Gibco). Cultured explants were treated with BDNF or MANF from
days 1 to 4. Cell migration distance was examined on days 1, 4,
and 7. Explants were transduced with LV-hDCX-GFP, LV-hDCX-
myrAkt-GFP, or LV-hDCX-hMANF-IRES-GFP on day 1 and cell
migration distance was examined on day 1 and 6. At the end of the
experiment, explants were ﬁxed in 4% PFA. Explants were blocked
with 3% donkey serum (0.2% Triton X-100 in PBS) and then incu-
bated with primary goat anti-DCX (1:400, Santa Cruz) and rabbit
anti-GFP (1:1,000, Chemicon International) antibodies for 24 hr
and with secondary antibodies as described below.
Western Blotting
Explant samples were homogenized in lysis buffer (5 mMHEPES, pH
7.4; 320 mM sucrose; 1 mMEDTA; 0.1% SDS; and protease inhibitors
[Roche]). Protein concentrations were determined using a BSA kit
(Pierce). Samples were diluted in lysis buffer and Laemmli buffer con-
taining 2% mercaptoethanol, and 20 mg protein was loaded on a 10%
SDS-polyacrylamide gel. The nitrocellulose membrane was blocked in
5% skimmed milk and incubated with rabbit anti-b-tubulin III (Tuj1,
1:1,000, Covance), mouse anti-GFAP (1:1,000, Millipore), rabbit anti-
pERK (1:1,000, Cell Signaling Technology), rabbit anti-ERK (1:1,000,
Cell Signaling Technology), rabbit anti-pAkt (1:1,000, Cell SignalingTechnology), rabbit anti-Akt (1:1,000, Cell Signaling Technology),
rabbit anti-phospho-S6 Ribosomal protein (1:1,000, Cell Signaling
Technology), rabbit anti-pSTAT3-Ser727 (1:500, Cell Signaling Tech-
nology), rabbit anti-pSTAT3-Tyr705 (1:500, Cell Signaling Technol-
ogy), rabbit anti-STAT3 (1:500, Santa Cruz Biotechnology), goat
anti-GRP78 (1:500, Santa Cruz Biotechnology), and mouse anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1:2,000, Milli-
pore) antibodies at 4C overnight, and then probed with goat anti-
mouse or goat anti-rabbit IR-Dye 670 or 800 secondary antibodies
(LI-COR Biosciences) in 5% milk in PBS with Tween 20 (PBS-T)
for 2 hr. Membranes were imaged using a LI-COR Odyssey scanner
and analyzed using Odyssey 3.0 analytical software (LI-COR Biosci-
ences, Lincoln, NE).
Animal Experiments
All animals were housed under a 12-hr “light-dark” or then “lights on
and dark” cycle with ad libitum access to food and water. All exper-
imental procedures were performed according to the 3R principles of
the EU directive 2010/63/EU and local laws and regulations (Finnish
Act on the Protection of Animals Used for Scientiﬁc or Educational
Purposes [497/2013] and Government Decree on the Protection of
Animals Used for Scientiﬁc or Educational Purposes [564/2013]).
All experiments were approved by the National Animal Experiment
Board (ESAVI/5459/04.10.03/2011 and ESAVI/7812/04.10.07/2015).
dMCAo
Ligation of the right middle cerebral artery (MCA) and bilateral com-
mon carotid arteries (CCAs) was performed on adult male Sprague-
Dawley rats (220–260 g, Envigo) under chloral hydrate (0.4 g/kg
intraperitoneally [i.p.]) anesthesia as described.77,78 Brieﬂy, bilateral
CCAs were isolated through a ventral midline cervical incision.
Rats were placed in a stereotaxic apparatus and a craniotomy was
made over the right hemisphere. The right MCA was ligated with a
10-0 suture, and bilateral CCAs were ligated with arterial clamps
for 90 min. After 90 min of ischemia, the suture around the MCA
and arterial clips was removed. After recovery from anesthesia, the
rats were returned to their home cage. Core temperature was main-
tained at 37C. In experiments comparing the effect of GDNF and
MANF on SVZ cells, the animals were examined using the Bederson’s
neurological test and body-asymmetry analysis 2 days after dMCAo.
Behavioral analysis was carried out in a blinded fashion, and the
experimenter did not know any surgical information. On the basis
of the scores, the animals were then divided into three groups, keeping
the average score of the three groups equal. On day 3, 7, and 10 after
dMCAo surgery, hGDNF protein (10 mg), rhMANF protein (10 mg),
or PBS was injected into the right lateral ventricle with the stereotaxic
coordinates A/P 0.3; L/M +1.3; D/V 4.5 (from the surface of the
skull) under isoﬂurane anesthesia. 4 mL solution was injected at a
rate of 0.5 mL/min, and the needle (WPI nanoﬁl 33G) was retained
in place for 5 min after the injection.
To explore the long-term effect of MANF on the infarct boundary, 20
rats were implanted with infusion cannulas connected to subcutane-
ously placed osmotic minipumps (Alzet model 2002, Durect, CA,Molecular Therapy Vol. 26 No 1 January 2018 251
Molecular TherapyUSA) into the peri-infarction zone, with coordinates A/P 0.5;
L/M +1.9; D/V 2.5, and secured to the skull using three stainless
steel screws and polycarboxylate cement (Aqualox; VOCO, Ger-
many). Pumps were ﬁlled with recombinant human GDNF, MANF
(0.25 mg/mL), or PBS from post-stroke day 3 to day 16 (12 mL/day),
after which the pumps were removed.
BrdU Injections
To study the effect of GDNF andMANF on proliferation of NSCs and
NPCs, BrdU (50 mg/kg) was administered i.p. twice per day on days
3–10 after dMCAo (Figure 7A). In order to study the migration and
differentiation of NPCs, i.p. injections of BrdU (50 mg/kg) were
administered 3 times, with 2 hr intervals at day 2 after dMCAo before
long-term GDNF or MANF infusion.
Immunofluorescence Staining
Cells or SVZ explant cultures cells were permeabilized for 15min with
0.1% Triton X-100 in PBS and blocked for 1 hr with PBS containing
0.1% Triton X-100, 2% BSA, and 5% horse serum. Cells or explants
were then incubated overnight with rabbit anti-MANF (1:1,000, Ico-
sagen), rabbit anti-GFP (1:1,000, Life Technologies), or goat anti-
DCX (1:400, DCX; Santa Cruz Biotechnology) in PBS containing
0.1% Triton X-100 and 5% normal horse serum at 4C with gentle
shaking, followed by 1 hr incubation with corresponding Alexa Fluor
488- or 568-conjugated secondary antibodies (1:500, Life Technolo-
gies). Finally, cells were stained with 5 mg/mL solution of DAPI
(Sigma-Aldrich) in PBS. Fluorescence images were captured with
Cellomics CellInsight (Thermo Scientiﬁc) equipped with Olympus
UPlanFL N 10/0.3 and Olympus LUCPlanFL N 20/0.45 objectives
and acquired with the CellProﬁler project 2.1.1 software.79,80 For SVZ
explant cultures, the migration distance of migratory chains was
measured for DCX+ cells using ImageJ software. The three longest
migratory chains per explant were used to estimate the maximum
migration distance.
Histology, Immunohistochemical, and Immunofluorescent
Staining of Brain Sections
Brains were ﬁxed in 4% PFA and embedded in parafﬁn. Brains were
sectioned into 5-mm-thick coronal or sagittal sections. Slides were de-
parafﬁnized and re-hydrated through a graded alcohol series before
being subjected to antigen retrieval in 10 mM sodium citrate buffer,
pH 6.0, or 0.05% citraconic anhydride buffer, pH 7.4, at 120C for
10 min. The sections were incubated with one of the following pri-
mary antibodies: rabbit anti-MANF (Isocagen, 1:1,000), goat anti-
DCX (Santa Cruz, 1:400), mouse anti-Nestin (Millipore, 1:400),
sheep anti-BrdU (Abcam, 1:200), mouse anti-GFAP (Millipore,
1:500), mouse anti-NeuN (Millipore,1:400), rabbit anti-GFAP
(Sigma-Aldrich, 1:500), and mouse anti-NG2 (Millipore, 1:200) in
TBS-T with 5% serum chosen based on the secondary antibody at
4C overnight. For immunoﬂuorescent staining, appropriate second-
ary antibodies conjugated to Alexa Fluor 488 or 568 (Life Technolo-
gies, 1:500) were used. Fluorescence images were captured with a
Zeiss AxioImager M2 482 epiﬂuorescence microscope equipped
with a 483 AxioCam HRm camera. Images were acquired with the252 Molecular Therapy Vol. 26 No 1 January 2018AxioVision4 software. For immunohistochemistry, biotinylated sec-
ondary antibody and peroxidase-conjugated streptavidin Vectastain
ABC-detection system (Vector Laboratories) were used. Sections
were developed with diaminobenzidine peroxidase substrate (Vector
Laboratories) and imaged with a Pannoramic 250 Flash II slide scan-
ner (3DHistech, http://www.biocenter.helsinki.ﬁ/bi/histoscanner/
index.html).
For quantiﬁcation of DCX+ cells, three to six sections through the
lesion (1.6–3.0 mm lateral to the bregma) were examined. The inter-
val between the sections was 0.5 mm. For quantiﬁcation of BrdU
immunoﬂuorescent staining, three sections, 600 mm apart, starting
at 1.6 mm lateral to the bregma, were sampled for each brain, and
the number of BrdU+ cells in the SVZ was counted with Image-Pro
Analyzer 7.0. Double immunoﬂuorescence (BrdU/DCX, BrdU/
GFAP, and BrdU/NG2) was quantiﬁed from images taken at 20 
magniﬁcation. For quantiﬁcation of neuronal differentiation
(BrdU+/NeuN+ cells), immunoﬂuorescence images were taken from
ﬁve sections beginning at 2.0 mm anterior to the bregma and until
0.0 mm. The images were taken at 40  magniﬁcation with a
400 mm interval.
Statistical Analysis
Values are presented as mean ± SEM. Unpaired Student’s t test and
ANOVA with Fisher’s LSD or Tukey’s post hoc test were used for
statistical analysis. A statistically signiﬁcant difference was deﬁned
as p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one ﬁgure and one table and can
be found with this article online at https://doi.org/10.1016/j.ymthe.
2017.09.019.
AUTHOR CONTRIBUTIONS
K.T.: conception and design, collection and assembly of data, data
analysis and interpretation, manuscript writing, and ﬁnal approval
of the manuscript; J.E.A.: collection or assembly of data, provision
of study material, and writing and ﬁnal approval of the manuscript;
A.D.: manuscript writing, ﬁnal approval of the manuscript, and
design and planning of NSC experiments and lentivirus vectors;
K.K.: design and making the LV construct and writing and ﬁnal
approval of the manuscript; R.K.T.: designing the experiments,
manuscript writing, and ﬁnal approval of the manuscript; M.L.:
design and production of MANF ko mice, manuscript writing, and
ﬁnal approval of the manuscript; M.A.: conception and design, data
analysis, manuscript writing, ﬁnancial support, and writing and ﬁnal
approval of the manuscript.
CONFLICTS OF INTEREST
The authors declare no conﬂict of interests.
ACKNOWLEDGMENTS
We thank Congjun Zheng for primary cell cultures andM.Sc. Katrina
Albert and Ph.D. Sandya Narayanswami for proofreading the
www.moleculartherapy.orgmanuscript. We thankMart Saarma for his constructive comments to
the manuscript and support. This work was supported by Academy of
Finland grants 287843 (to A.D.) and 250275, 256398, 281394, and
309489 (to M.A.), TEKES 3iRegeneration, the Sigrid Juselius Founda-
tion, and the Instrumentarium Science Foundation.
REFERENCES
1. Aimone, J.B., Li, Y., Lee, S.W., Clemenson, G.D., Deng, W., and Gage, F.H. (2014).
Regulation and function of adult neurogenesis: from genes to cognition. Physiol.
Rev. 94, 991–1026.
2. Tobin, M.K., Bonds, J.A., Minshall, R.D., Pelligrino, D.A., Testai, F.D., and Lazarov,
O. (2014). Neurogenesis and inﬂammation after ischemic stroke: what is known and
where we go from here. J. Cereb. Blood Flow Metab. 34, 1573–1584.
3. Ming, G.L., and Song, H. (2011). Adult neurogenesis in the mammalian brain: signif-
icant answers and signiﬁcant questions. Neuron 70, 687–702.
4. Lepousez, G., Valley, M.T., and Lledo, P.M. (2013). The impact of adult neurogenesis
on olfactory bulb circuits and computations. Annu. Rev. Physiol. 75, 339–363.
5. Ihrie, R.A., and Alvarez-Buylla, A. (2011). Lake-front property: a unique germinal
niche by the lateral ventricles of the adult brain. Neuron 70, 674–686.
6. Kokaia, Z., and Lindvall, O. (2003). Neurogenesis after ischaemic brain insults. Curr.
Opin. Neurobiol. 13, 127–132.
7. Barkho, B.Z., and Zhao, X. (2011). Adult neural stem cells: response to stroke
injury and potential for therapeutic applications. Curr. Stem Cell Res. Ther. 6,
327–338.
8. Thored, P., Wood, J., Arvidsson, A., Cammenga, J., Kokaia, Z., and Lindvall, O.
(2007). Long-term neuroblast migration along blood vessels in an area with tran-
sient angiogenesis and increased vascularization after stroke. Stroke 38, 3032–
3039.
9. Parent, J.M., Vexler, Z.S., Gong, C., Derugin, N., and Ferriero, D.M. (2002). Rat fore-
brain neurogenesis and striatal neuron replacement after focal stroke. Ann. Neurol.
52, 802–813.
10. Kreuzberg, M., Kanov, E., Timofeev, O., Schwaninger, M., Monyer, H., and
Khodosevich, K. (2010). Increased subventricular zone-derived cortical neurogenesis
after ischemic lesion. Exp. Neurol. 226, 90–99.
11. Arvidsson, A., Collin, T., Kirik, D., Kokaia, Z., and Lindvall, O. (2002). Neuronal
replacement from endogenous precursors in the adult brain after stroke. Nat. Med.
8, 963–970.
12. Luo, Y., Kuo, C.C., Shen, H., Chou, J., Greig, N.H., Hoffer, B.J., and Wang, Y. (2009).
Delayed treatment with a p53 inhibitor enhances recovery in stroke brain. Ann.
Neurol. 65, 520–530.
13. Airaksinen, M.S., and Saarma, M. (2002). The GDNF family: signalling, biological
functions and therapeutic value. Nat. Rev. Neurosci. 3, 383–394.
14. Gordon, T. (2009). The role of neurotrophic factors in nerve regeneration.
Neurosurg. Focus 26, E3.
15. Pozas, E., and Ibáñez, C.F. (2005). GDNF and GFRalpha1 promote differentiation
and tangential migration of cortical GABAergic neurons. Neuron 45, 701–713.
16. Paratcha, G., Ibáñez, C.F., and Ledda, F. (2006). GDNF is a chemoattractant factor for
neuronal precursor cells in the rostral migratory stream. Mol. Cell. Neurosci. 31,
505–514.
17. Marks, C., Belluscio, L., and Ibáñez, C.F. (2012). Critical role of GFRa1 in the
development and function of the main olfactory system. J. Neurosci. 32,
17306–17320.
18. Kobayashi, T., Ahlenius, H., Thored, P., Kobayashi, R., Kokaia, Z., and Lindvall, O.
(2006). Intracerebral infusion of glial cell line-derived neurotrophic factor promotes
striatal neurogenesis after stroke in adult rats. Stroke 37, 2361–2367.
19. Schäbitz, W.R., Steigleder, T., Cooper-Kuhn, C.M., Schwab, S., Sommer, C.,
Schneider, A., and Kuhn, H.G. (2007). Intravenous brain-derived neurotrophic factor
enhances poststroke sensorimotor recovery and stimulates neurogenesis. Stroke 38,
2165–2172.20. Yu, S.J., Tseng, K.Y., Shen, H., Harvey, B.K., Airavaara, M., and Wang, Y. (2013).
Local administration of AAV-BDNF to subventricular zone induces functional recov-
ery in stroke rats. PLoS One 8, e81750.
21. Mizobuchi, N., Hoseki, J., Kubota, H., Toyokuni, S., Nozaki, J., Naitoh, M., Koizumi,
A., and Nagata, K. (2007). ARMET is a soluble ER protein induced by the unfolded
protein response via ERSE-II element. Cell Struct. Funct. 32, 41–50.
22. Apostolou, A., Shen, Y., Liang, Y., Luo, J., and Fang, S. (2008). Armet, a UPR-upre-
gulated protein, inhibits cell proliferation and ER stress-induced cell death. Exp. Cell
Res. 314, 2454–2467.
23. Glembotski, C.C., Thuerauf, D.J., Huang, C., Vekich, J.A., Gottlieb, R.A., and
Doroudgar, S. (2012). Mesencephalic astrocyte-derived neurotrophic factor protects
the heart from ischemic damage and is selectively secreted upon sarco/endoplasmic
reticulum calcium depletion. J. Biol. Chem. 287, 25893–25904.
24. Henderson, M.J., Richie, C.T., Airavaara, M., Wang, Y., and Harvey, B.K.
(2013). Mesencephalic astrocyte-derived neurotrophic factor (MANF) secretion
and cell surface binding are modulated by KDEL receptors. J. Biol. Chem. 288,
4209–4225.
25. Lindholm, P., Voutilainen, M.H., Laurén, J., Peränen, J., Leppänen, V.M., Andressoo,
J.O., Lindahl, M., Janhunen, S., Kalkkinen, N., Timmusk, T., et al. (2007). Novel neu-
rotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.
Nature 448, 73–77.
26. Lindholm, P., Peränen, J., Andressoo, J.O., Kalkkinen, N., Kokaia, Z., Lindvall, O.,
Timmusk, T., and Saarma, M. (2008). MANF is widely expressed in mammalian tis-
sues and differently regulated after ischemic and epileptic insults in rodent brain.
Mol. Cell. Neurosci. 39, 356–371.
27. Lindahl, M., Danilova, T., Palm, E., Lindholm, P., Võikar, V., Hakonen, E., Ustinov, J.,
Andressoo, J.O., Harvey, B.K., Otonkoski, T., et al. (2014). MANF is indispensable for
the proliferation and survival of pancreatic b cells. Cell Rep. 7, 366–375.
28. Airavaara, M., Shen, H., Kuo, C.C., Peränen, J., Saarma, M., Hoffer, B., and
Wang, Y. (2009). Mesencephalic astrocyte-derived neurotrophic factor reduces
ischemic brain injury and promotes behavioral recovery in rats. J. Comp.
Neurol. 515, 116–124.
29. Airavaara, M., Chiocco, M.J., Howard, D.B., Zuchowski, K.L., Peränen, J., Liu, C.,
Fang, S., Hoffer, B.J., Wang, Y., and Harvey, B.K. (2010). Widespread cortical expres-
sion of MANF by AAV serotype 7: localization and protection against ischemic brain
injury. Exp. Neurol. 225, 104–113.
30. Neves, J., Zhu, J., Sousa-Victor, P., Konjikusic, M., Riley, R., Chew, S., Qi, Y., Jasper,
H., and Lamba, D.A. (2016). Immune modulation by MANF promotes tissue repair
and regenerative success in the retina. Science 353, aaf3646.
31. Voutilainen, M.H., De Lorenzo, F., Stepanova, P., Back, S., Yu, L.Y., Lindholm, P.,
Pörsti, E., Saarma, M., Männistö, P.T., and Tuominen, R.K. (2017). Evidence for
an additive neurorestorative effect of simultaneously administered CDNF and
GDNF in hemiparkinsonian rats: implications for different mechanism of action.
eNeuro 4.
32. Hao, F., Yang, C., Chen, S.S., Wang, Y.Y., Zhou, W., Hao, Q., Lu, T., Hoffer, B., Zhao,
L.R., Duan, W.M., et al. (2017). Long-term protective effects of AAV9-mesencephalic
astrocyte-derived neurotrophic factor gene transfer in parkinsonian rats. Exp.
Neurol. 291, 120–133.
33. Hellman, M., Arumäe, U., Yu, L.Y., Lindholm, P., Peränen, J., Saarma, M., and Permi,
P. (2011). Mesencephalic astrocyte-derived neurotrophic factor (MANF) has a
unique mechanism to rescue apoptotic neurons. J. Biol. Chem. 286, 2675–2680.
34. Voutilainen, M.H., Bäck, S., Pörsti, E., Toppinen, L., Lindgren, L., Lindholm, P.,
Peränen, J., Saarma, M., and Tuominen, R.K. (2009). Mesencephalic astrocyte-
derived neurotrophic factor is neurorestorative in rat model of Parkinson’s disease.
J. Neurosci. 29, 9651–9659.
35. Ries, V., Henchcliffe, C., Kareva, T., Rzhetskaya, M., Bland, R., During, M.J.,
Kholodilov, N., and Burke, R.E. (2006). Oncoprotein Akt/PKB induces trophic effects
in murine models of Parkinson’s disease. Proc. Natl. Acad. Sci. USA 103, 18757–
18762.
36. Dempsey, R.J., Sailor, K.A., Bowen, K.K., Türeyen, K., and Vemuganti, R. (2003).
Stroke-induced progenitor cell proliferation in adult spontaneously hypertensive
rat brain: effect of exogenous IGF-1 and GDNF. J. Neurochem. 87, 586–597.Molecular Therapy Vol. 26 No 1 January 2018 253
Molecular Therapy37. Mätlik, K., Yu, L.Y., Eesmaa, A., Hellman, M., Lindholm, P., Peränen, J., Galli, E.,
Anttila, J., Saarma, M., Permi, P., et al. (2015). Role of two sequence motifs of mesen-
cephalic astrocyte-derived neurotrophic factor in its survival-promoting activity. Cell
Death Dis. 6, e2032.
38. Petrova, P., Raibekas, A., Pevsner, J., Vigo, N., Anaﬁ, M., Moore, M.K., Peaire, A.E.,
Shridhar, V., Smith, D.I., Kelly, J., et al. (2003). MANF: a new mesencephalic, astro-
cyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J. Mol.
Neurosci. 20, 173–188.
39. Lindahl, M., Saarma, M., and Lindholm, P. (2017). Unconventional neurotrophic fac-
tors CDNF and MANF: Structure, physiological functions and therapeutic potential.
Neurobiol. Dis. 97 (Pt B), 90–102.
40. Palgi, M., Lindström, R., Peränen, J., Piepponen, T.P., Saarma, M., and Heino, T.I.
(2009). Evidence that DmMANF is an invertebrate neurotrophic factor supporting
dopaminergic neurons. Proc. Natl. Acad. Sci. USA 106, 2429–2434.
41. Lindberg, O.R., Brederlau, A., Jansson, A., Nannmark, U., Cooper-Kuhn, C., and
Kuhn, H.G. (2012). Characterization of epidermal growth factor-induced dysplasia
in the adult rat subventricular zone. Stem Cells Dev. 21, 1356–1366.
42. Lindberg, O.R., Brederlau, A., and Kuhn, H.G. (2014). Epidermal growth factor treat-
ment of the adult brain subventricular zone leads to focal microglia/macrophage
accumulation and angiogenesis. Stem Cell Reports 2, 440–448.
43. Yang, S., Huang, S., Gaertig, M.A., Li, X.J., and Li, S. (2014). Age-dependent decrease
in chaperone activity impairs MANF expression, leading to Purkinje cell degenera-
tion in inducible SCA17 mice. Neuron 81, 349–365.
44. Gartsbein, M., Alt, A., Hashimoto, K., Nakajima, K., Kuroki, T., and Tennenbaum, T.
(2006). The role of protein kinase C delta activation and STAT3 Ser727 phosphory-
lation in insulin-induced keratinocyte proliferation. J. Cell Sci. 119, 470–481.
45. Corbit, K.C., Soh, J.W., Yoshida, K., Eves, E.M., Weinstein, I.B., and Rosner, M.R.
(2000). Different protein kinase C isoforms determine growth factor speciﬁcity in
neuronal cells. Mol. Cell. Biol. 20, 5392–5403.
46. Yu, H., Pardoll, D., and Jove, R. (2009). STATs in cancer inﬂammation and immu-
nity: a leading role for STAT3. Nat. Rev. Cancer 9, 798–809.
47. Bauer, S. (2009). Cytokine control of adult neural stem cells. Ann. N Y Acad. Sci.
1153, 48–56.
48. Islam, O., Gong, X., Rose-John, S., and Heese, K. (2009). Interleukin-6 and neural
stem cells: more than gliogenesis. Mol. Biol. Cell 20, 188–199.
49. Xia, X.G., Hofmann, H.D., Deller, T., and Kirsch, M. (2002). Induction of STAT3
signaling in activated astrocytes and sprouting septal neurons following entorhinal
cortex lesion in adult rats. Mol. Cell. Neurosci. 21, 379–392.
50. Herrmann, J.E., Imura, T., Song, B., Qi, J., Ao, Y., Nguyen, T.K., Korsak, R.A., Takeda,
K., Akira, S., and Sofroniew, M.V. (2008). STAT3 is a critical regulator of astrogliosis
and scar formation after spinal cord injury. J. Neurosci. 28, 7231–7243.
51. Kang, M.J., Park, S.Y., and Han, J.S. (2016). Hippocalcin is required for astrocytic dif-
ferentiation through activation of Stat3 in hippocampal neural precursor cells. Front.
Mol. Neurosci. 9, 110.
52. Ng, D.C., Lin, B.H., Lim, C.P., Huang, G., Zhang, T., Poli, V., and Cao, X. (2006). Stat3
regulates microtubules by antagonizing the depolymerization activity of stathmin.
J. Cell Biol. 172, 245–257.
53. Zhou, L., and Too, H.P. (2011). Mitochondrial localized STAT3 is involved in NGF
induced neurite outgrowth. PLoS One 6, e21680.
54. Sheu, J.Y., Kulhanek, D.J., and Eckenstein, F.P. (2000). Differential patterns of ERK
and STAT3 phosphorylation after sciatic nerve transection in the rat. Exp. Neurol.
166, 392–402.
55. Huang, C., Jacobson, K., and Schaller, M.D. (2004). MAP kinases and cell migration.
J. Cell Sci. 117, 4619–4628.
56. Anand-Apte, B., Zetter, B.R., Viswanathan, A., Qiu, R.G., Chen, J., Ruggieri, R., and
Symons, M. (1997). Platelet-derived growth factor and ﬁbronectin-stimulated migra-
tion are differentially regulated by the Rac and extracellular signal-regulated kinase
pathways. J. Biol. Chem. 272, 30688–30692.
57. Webb, D.J., Donais, K., Whitmore, L.A., Thomas, S.M., Turner, C.E., Parsons, J.T.,
and Horwitz, A.F. (2004). FAK-Src signalling through paxillin, ERK and MLCK reg-
ulates adhesion disassembly. Nat. Cell Biol. 6, 154–161.254 Molecular Therapy Vol. 26 No 1 January 201858. Chen, P., Murphy-Ullrich, J.E., and Wells, A. (1996). A role for gelsolin in actu-
ating epidermal growth factor receptor-mediated cell motility. J. Cell Biol. 134,
689–698.
59. Giroux, S., Tremblay, M., Bernard, D., Cardin-Girard, J.F., Aubry, S., Larouche, L.,
Rousseau, S., Huot, J., Landry, J., Jeannotte, L., et al. (1999). Embryonic death of
Mek1-deﬁcient mice reveals a role for this kinase in angiogenesis in the labyrinthine
region of the placenta. Curr. Biol. 9, 369–372.
60. Sakata, H., Narasimhan, P., Niizuma, K., Maier, C.M., Wakai, T., and Chan, P.H.
(2012). Interleukin 6-preconditioned neural stem cells reduce ischaemic injury in
stroke mice. Brain 135, 3298–3310.
61. Zhao, H., Cheng, L., Du, X., Hou, Y., Liu, Y., Cui, Z., and Nie, L. (2016).
Transplantation of cerebral dopamine neurotrophic factor transducted BMSCs in
contusion spinal cord injury of rats: promotion of nerve regeneration by alleviating
neuroinﬂammation. Mol. Neurobiol. 53, 187–199.
62. Chapman, K.Z., Ge, R., Monni, E., Tatarishvili, J., Ahlenius, H., Arvidsson, A.,
Ekdahl, C.T., Lindvall, O., and Kokaia, Z. (2015). Inﬂammation without neuronal
death triggers striatal neurogenesis comparable to stroke. Neurobiol. Dis. 83, 1–15.
63. Alam,M.A., SubramanyamRallabandi, V.P., and Roy, P.K. (2016). Systems biology of
immunomodulation for post-stroke neuroplasticity: multimodal implications of
pharmacotherapy and neurorehabilitation. Front. Neurol. 7, 94.
64. Chen, L., Feng, L., Wang, X., Du, J., Chen, Y., Yang, W., Zhou, C., Cheng, L., Shen, Y.,
Fang, S., et al. (2015). Mesencephalic astrocyte-derived neurotrophic factor is
involved in inﬂammation by negatively regulating the NF-kB pathway. Sci. Rep. 5,
8133.
65. Stratoulias, V., and Heino, T.I. (2015). MANF silencing, immunity induction or auto-
phagy trigger an unusual cell type in metamorphosing Drosophila brain. Cell. Mol.
Life Sci. 72, 1989–2004.
66. Shen, Y., Sun, A., Wang, Y., Cha, D., Wang, H., Wang, F., Feng, L., Fang, S., and
Shen, Y. (2012). Upregulation of mesencephalic astrocyte-derived neurotrophic
factor in glial cells is associated with ischemia-induced glial activation.
J. Neuroinﬂammation 9, 254.
67. Lahti, L., Saarimäki-Vire, J., Rita, H., and Partanen, J. (2011). FGF signaling gradient
maintains symmetrical proliferative divisions of midbrain neuronal progenitors. Dev.
Biol. 349, 270–282.
68. Saarimäki-Vire, J., Peltopuro, P., Lahti, L., Naserke, T., Blak, A.A., Vogt Weisenhorn,
D.M., Yu, K., Ornitz, D.M., Wurst, W., and Partanen, J. (2007). Fibroblast growth fac-
tor receptors cooperate to regulate neural progenitor properties in the developing
midbrain and hindbrain. J. Neurosci. 27, 8581–8592.
69. Kalluri, H.S., Eickstaedt, J., and Dempsey, R.J. (2007). Oxygen glucose deprivation in-
hibits the growth and ERK phosphorylation of neural progenitor cells in vitro.
Neurosci. Lett. 426, 145–148.
70. Riccardi, C., and Nicoletti, I. (2006). Analysis of apoptosis by propidium iodide stain-
ing and ﬂow cytometry. Nat. Protoc. 1, 1458–1461.
71. Liu, X., Constantinescu, S.N., Sun, Y., Bogan, J.S., Hirsch, D., Weinberg, R.A., and
Lodish, H.F. (2000). Generation of mammalian cells stably expressing multiple genes
at predetermined levels. Anal. Biochem. 280, 20–28.
72. Garcia-Gonzalez, D., Khodosevich, K., Watanabe, Y., Rollenhagen, A., Lubke, J.H.R.,
and Monyer, H. (2017). Serotonergic projections govern postnatal neuroblast migra-
tion. Neuron 94, 534–549.
73. Khodosevich, K., Zuccotti, A., Kreuzberg, M.M., Le Magueresse, C., Frank, M.,
Willecke, K., and Monyer, H. (2012). Connexin45 modulates the proliferation of
transit-amplifying precursor cells in the mouse subventricular zone. Proc. Natl.
Acad. Sci. USA 109, 20107–20112.
74. Ding, B., and Kilpatrick, D.L. (2013). Lentiviral vector production, titration, and
transduction of primary neurons. Methods Mol. Biol. 1018, 119–131.
75. Li, L., and Hu, G.K. (2015). Pink1 protects cortical neurons from thapsigargin-
induced oxidative stress and neuronal apoptosis. Biosci. Rep. 35.
76. Galli, E., Härkönen, T., Sainio, M.T., Ustav, M., Toots, U., Urtti, A., Yliperttula, M.,
Lindahl, M., Knip, M., Saarma, M., et al. (2016). Increased circulating concentrations
of mesencephalic astrocyte-derived neurotrophic factor in children with type 1 dia-
betes. Sci. Rep. 6, 29058.
www.moleculartherapy.org77. Chen, S.T., Hsu,C.Y.,Hogan, E.L.,Maricq,H., andBalentine, J.D. (1986).Amodel of focal
ischemic stroke in the rat: reproducible extensive cortical infarction. Stroke 17, 738–743.
78. Mätlik, K., Abo-Ramadan, U., Harvey, B.K., Arumäe, U., and Airavaara, M. (2014).
AAV-mediated targeting of gene expression to the peri-infarct region in rat cortical
stroke model. J. Neurosci. Methods 236, 107–113.
79. Kamentsky, L., Jones, T.R., Fraser, A., Bray, M.A., Logan, D.J., Madden, K.L., Ljosa,
V., Rueden, C., Eliceiri, K.W., and Carpenter, A.E. (2011). Improved structure, func-tion and compatibility for CellProﬁler: modular high-throughput image analysis soft-
ware. Bioinformatics 27, 1179–1180.
80. Jones, T.R., Carpenter, A.E., Lamprecht, M.R., Moffat, J., Silver, S.J.,
Grenier, J.K., Castoreno, A.B., Eggert, U.S., Root, D.E., Golland, P., et al.
(2009). Scoring diverse cellular morphologies in image-based screens with
iterative feedback and machine learning. Proc. Natl. Acad. Sci. USA 106,
1826–1831.Molecular Therapy Vol. 26 No 1 January 2018 255
